Skip to main content

Table 3 ExAblate treatments in 2003–2011

From: Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study

Year Mean age, years (SD) Mean BMI (SD) Mean SSS (SD) Mean uterine volume, ml (SD) Mean total fibroid volume, ml (SD) Mean %NPV (SD) % HI dominant fibroid
2003 41.97 (5.44) 24.95 (4.05) 64.79 (17.47) 809.73 (445.48) 333.8 (209.75) 41.22 (25.66) 29.2
2004 43.87 (5.09) 24.11 (3.17) 62.1 (14.05) 734.20 (323.86) 387.0 (198.31) 47.33 (23.21) 29.0
2005 43.67 (8.93) 27.23 (4.14) 78.12 (16.24) 949.51 (383.33) 544.23 (276.52) 33.4 (20.34) 30.8
2006 42.74 (10.20) 25.00 (4.39) 64.1 (19.13) 958.1 (469.46) 495.1 (291.49) 39.4 (24.31) 26.9
2007 42.25 (5.93) 26.10 (5.55) 59.4 (16.93) 828.65 (446.98) 431.7 (289.64) 40.7 (22.04) 32.0
2008 43.15 (6.97) 23.75 (3.08) 64.1 (19.26) 861.90 (469.25) 445.1 (314.95) 44.54 (21.10) 36.4
2009 41.1 (6.00) 25.37 (5.97) 57.9 (19.04) 611.01 (249.98)*a 314.3 (195.75) 51.53 (19.63) 25.92
2010 40.4 (7.67) 25.5 (4.00) 65.46 (19.18) 658.38 (296.37)**a 319.2 (241.88) 50.49 (18.23) 13.78*****b
2011 (ExAblate 2100) 39.47 (6.53) 23.41 (4.25) 61.02 (17.13) 655.06 (257.49)***a 305.12 (203.43) 54.78 (19.01)****a 17.1
  1. BMI body mass index, SSS symptom severity score, NPV non-perfused volume, HI hyper-intensity of treated fibroid.
  2. *p = 0.004.
  3. **p = 0.015.
  4. ***p = 0.005.
  5. ****p = 0.007.
  6. *****p = 0.049.
  7. aMann-Whitney test.
  8. bChi-square test.